IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19

NEXT STORY
Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
PREV STORY
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease

RedHill has received Notices of Allowance for two new patents covering RHB-104 in the ...

author_avatar
NASDAQ Market News

Clear Aligners Market Size, Share & Trends Analysis Report By Age, By End Use, By Region And Segment Forecasts, 2021 – 2028

author_avatar
NASDAQ Market News

Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment

author_avatar
NASDAQ Market News